A control circuit includes one or more processors and a computer readable medium storing instructions that, when executed by the one or more processors, cause the control circuit to perform functions. The functions include providing a load current that flows into a digital load and determining a magnitude of a difference between a load voltage across the digital load and a reference voltage. The functions also includes determining a digital state of the digital load and adjusting the load current based on (i) the magnitude of the difference between the load voltage and the reference voltage and (ii) the digital state of the digital load.
In some embodiments, a computer-implemented method of detecting a presence of a predetermined fusion gene in a biological sample is provided. A computing system generates an alignment of a read sequence to a reference genome. The alignment includes a first alignment result and a second alignment result. The computing system determines a breakpoint location indicated by the first alignment result and the second alignment result, distances between coordinates of the breakpoint location and coordinates of one or more expected breakpoint locations associated with the predetermined fusion gene, a gap size value and an overlap size value. In response to determining that the gap size value is less than a gap size value threshold, the overlap size value is less than an overlap size value threshold, and the distances are less than a breakpoint distance threshold, the computing system generates an indication of the presence of the predetermined fusion gene.
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 30/10 - Alignement de séquence; Recherche d’homologie
G16B 40/00 - TIC spécialement adaptées aux biostatistiques; TIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p.ex. extraction de connaissances ou détection de motifs
Antibodies that bind the tumor (T) antigen of the Merkel cell polyomavirus are disclosed. The antibodies can be use used in cell-based immunotherapies, antibody-based therapies, diagnostics, and detection assays, among other uses. Related diagnostics are also described
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
4.
N-Oxide and Ectoine Monomers, Polymers, Their Compositions, and Related Methods
N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p.ex. par magnétisme, par des ondes sonores
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
Described herein is an oral sampling device, as well as methods of making and using the oral sampling device. The oral sampling device is configured to be placed inside of a human mouth to capture an analyte(s) found in bodily fluid, such as saliva, produced within the mouth. An example oral sampling device includes a body, at least a portion of which is sized to fit inside of a mouth of a human, has an outer surface, and a recess(es) defined in the outer surface to capture the analyte(s) therein. In some examples, a material of the body within the recess was subjected to a surface treatment to promote the capture of the analyte(s). In some examples, the oral sampling device includes a flavored substance disposed on at least the portion of the body that is to be received inside of a human mouth.
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
7.
BACTERIAL DNA CYTOSINE DEAMINASES FOR MAPPING DNA METHYLATION SITES
The disclosure provides methods and related kits, reagents, and systems for selectively deaminating unmethylated cytosine residues in nucleic acid molecules. In some embodiments, the methods and related kits, reagents, and systems are applied for methods of detecting and/or mapping methylated cytosine residues in nucleic acids. The nucleic can be RNA or DNA. Some embodiments include contacting the polynucleic acid with a bacterial cytosine deaminase, for example DddA or SsdA, or functional fragments or derivatives thereof. Representative DddA and SsdA have sequences set forth in SEQ ID NOS:1 and 2, respectively. The bacterial cytosine deaminases of the disclosure are sensitive to methylation and, thus, deaminate only unmethylated cytosines to provide a cytosine to uracil conversion. The conversion can be detected as a C•G-to-T•A transitions in subsequent sequencing analysis.
C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase
8.
AUTOMATED DISPENSER FOR CASTING HIGH-VISCOSITY SCAFFOLD SOLUTIONS
A viscous material dispenser, including an extruder with an inlet, a barrel, and a nozzle, a pump configured to fit inside the barrel, a tube connected to the inlet, a first valve attached to a first arm of the tube, and a second valve attached to a second arm of the tube, where when the first valve is open and the second valve is closed, the plunger is depressed by the source of pressurized air, causing a viscous material to flow out of the nozzle. Further, a method of dispensing a viscous material using a viscous material dispenser including positioning a substrate underneath the nozzle, filling the barrel of the extruder with a viscous material, and dispensing the viscous material from the nozzle of the extruder and onto the substrate by opening the first valve and closing the second valve.
B65D 83/00 - Réceptacles ou paquets comportant des moyens particuliers pour distribuer leur contenu
B05C 17/015 - Outils à main ou appareils utilisant des outils tenus à la main pour appliquer ou étaler des liquides ou d'autres matériaux fluides sur des surfaces, pour enlever partiellement des liquides ou d'autres matériaux fluides des surfaces pour décharger par pression des matériaux à travers un orifice d'évacuation avec un piston actionné pneumatiquement ou analogue
B65D 83/64 - Contenu et propulseur séparés par un piston
Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
10.
COMPOSITIONS AND METHODS FOR CARDIOMYOCYTE TRANSPLANTATION
The present disclosure provides for the treatment of cardiac diseases and disorders using in vitro-differentiated cardiomyocytes. Such methods can take advantage of both autologous and allogeneic pluripotent stem cells.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
11.
SYNTHETIC INTERMEDIATES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR IMMUNE CELL THERAPIES
SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (USA)
Inventeur(s)
Sellers, Drew
Cardle, Ian
Abrégé
Example compositions, systems, devices, and methods are used for universal chimeric antigen receptor T (UCAR-T) cell therapy. An example method includes administering, to a subject, engineered immune cells that express a chimeric antigen receptor (CAR) including an extracellular component and an intracellular component linked by a transmembrane domain, wherein the extracellular component includes an intermediary-binding domain. The example method further includes administering, to the subject, a synthetic intermediary including a tag linked to an antigen binding domain, the tag specifically binding the intermediary-binding domain, the antigen binding domain specifically binding an antigen expressed on a surface of a target cell in the subject.
The Chancellor, Masters And Scholars Of The University Of Oxford (Royaume‑Uni)
The Institute of Cancer Research: Royal Cancer Hospital (Royaume‑Uni)
University of Washington (USA)
Inventeur(s)
Islam, Md. Saiful
Tumber, Anthony
Schofield, Christopher
Paschalis, Alec
Welti, Jonathan
Sharp, Adam
De Bono, Johann
Plymate, Stephen
Abrégé
The invention relates to methods for treating prostate cancer by targeting the generation of splice variants of the androgen receptor. In one aspect, this can be achieved by targeting JMJD6 to reduce the production of androgen receptor splice variants. The invention finds particular use in the treatment of prostate cancer that is resistant to conventional androgen therapy.
A61K 31/44 - Pyridines non condensées; Leurs dérivés hydrogénés
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A capacitive sensor system configured to measure capacitance, including a sample volume, a sample capacitive sensor configured to measure the capacitance of the sample volume without physical contact between the sample capacitive sensor and the sample volume, a control capacitive sensor, a differential sensing subsystem configured to measure a control sensor volume using the control capacitive sensor, and electrical circuitry connected to both the control capacitive sensor and the sample capacitive sensor.
G01F 23/263 - Indication ou mesure du niveau des liquides ou des matériaux solides fluents, p.ex. indication en fonction du volume ou indication au moyen d'un signal d'alarme en mesurant des variables physiques autres que les dimensions linéaires, la pression ou le poids, selon le niveau à mesurer, p.ex. par la différence de transfert de chaleur de vapeur ou d'eau en mesurant les variations de capacité ou l'inductance de condensateurs ou de bobines produites par la présence d'un liquide ou d'un matériau solide fluent dans des champs électriques ou électromagnétiques en mesurant les variations de capacité de condensateurs
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
Manoparticies that display clade la, clade lb, and clade 3 sarbecovirus receptor-binding domains and compositions thereof are provided, together with pharmaceutical compositions thereof and methods for using the nanoparticles and compositions to treat or limit Sarbecovirus infection.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
15.
METHODS AND COMPOSITIONS FOR T CELL DIFFERENTIATION
The technology described herein is directed to stromal-free methods of T cell differentiation using a soluble Notch ligand. Also described herein are soluble Notch oligomer complexes and compositions thereof, and methods for making the same. Further described herein are immune cells differentiated using stromal -free methods and compositions comprising such immune cells. In some embodiments, the immune cells can be genetically modified. In some embodiments, the immune cells or compositions comprising said immune cells can be administered to a patient as a cellular replacement therapy to treat a condition.
Apparatuses, systems, and methods for synthetic 3D digital microscopy image sets. A microscope captures a depth stack of a sample using a first labelling technique. A trained machine learning model generates a synthetic depth stack of images based on the imaged depth stack. The synthetic depth stack mimics the appearance of a second labelling technique, which is targeted to a tissue structure of interest. A segmentation mask is generated based on the synthetic depth stack. The machine learning model may be trained on depth stacks of samples prepared with both the first and the second labelling techniques.
G06V 20/70 - RECONNAISSANCE OU COMPRÉHENSION D’IMAGES OU DE VIDÉOS Éléments spécifiques à la scène Étiquetage du contenu de scène, p.ex. en tirant des représentations syntaxiques ou sémantiques
17.
METHODS AND SYSTEMS FOR LARGE SCALE SCAFFOLDING OF GENOME ASSEMBLIES
Computational methods used for large scale scaffolding of a genome assembly are provided. Such methods may include a step of applying a location clustering model to a test set of contigs to form two or more location cluster groups, each location cluster group comprising one or more location-clustered contigs; a step of applying an ordering model to each of the two or more location cluster groups to form an ordered set of one or more location-clustered contigs within each cluster group; and a step of applying an orienting model to each ordered set of one or more location-clustered contigs to assign a relative orientation to each of the location-clustered contigs within each location cluster group. In some aspects, the test set of contigs are generated from aligning a set of reads generated by a chromosome conformation analysis technique (e.g., Hi-C) with a draft assembly, a reference assembly, or both.
G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
G16B 30/10 - Alignement de séquence; Recherche d’homologie
Disclosed are de novo designed polypeptide agonists and antagonists of IL-21, conditionally-active IL-21 agonists and antagonists, and methods for using them to treat cancer or to modulate an immune response.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
The present disclosure provides a device for respiratory protection. The device includes a face shield having a first end and a second end opposite the first end. The device also includes a headband coupled to the first end of the face shield and the second end of the face shield. The device also includes an electrohydrodynamic (EHD) air filter system positioned along an entirety of a perimeter of the face shield.
A62B 23/02 - Filtres en vue de la protection des voies respiratoires pour appareils respiratoires
A62B 18/00 - Masques ou casques respiratoires, p.ex. pour assurer une protection contre les agents chimiques ou pour l'emploi à hautes altitudes
A62B 18/08 - Masques ou casques respiratoires, p.ex. pour assurer une protection contre les agents chimiques ou pour l'emploi à hautes altitudes - Parties constitutives des casques ou masques à gaz, p.ex. fenêtres, sangles, transmetteurs de voix, dispositifs de signalisation
22.
REPROGRAMMABLE SYSTEMS AND METHODS FOR CONTROLLING THE SAME
Described herein are reprogrammable systems and methods for controlling the same. The reprogrammable system comprises a first side configured to be reprogrammable in at least a first direction. The first side is formed by a reprogrammable structure having one or more layers stacked in a second direction. An individual layer of the one or more layers has repeating unit cells. A first unit cell of the repeating unit cells has elements. The elements are connected by connecting joints. A first unit cell of the repeating unit cells shares at least one element and/or at least one connecting joint with a second unit cell of the repeating unit cells.
G06F 30/23 - Optimisation, vérification ou simulation de l’objet conçu utilisant les méthodes des éléments finis [MEF] ou les méthodes à différences finies [MDF]
G06F 30/17 - Conception mécanique paramétrique ou variationnelle
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Disclosed herein are designed heterodimer proteins, monomeric polypeptides capable of forming heterodimer proteins, protein scaffolds including such polypeptides, and methods for using the heterodimer proteins and subunit polypeptides for designing logic gates.
C07K 14/435 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p.ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G06N 3/00 - Agencements informatiques fondés sur des modèles biologiques
G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p.ex. relations structurelles ou fonctionnelles ou alignement de structures
H03K 19/00 - Circuits logiques, c. à d. ayant au moins deux entrées agissant sur une sortie; Circuits d'inversion
25.
METHODS AND SYSTEMS FOR FORMING MICROCELLULAR BUBBLES IN SELECTED PORTION OF A THERMOPLASTIC MEMBER
Method and system for forming of microcellular bubbles within a thermoplastic member employ an energy beam to form the microcellular bubbles within a selected portion of the thermoplastic member. A method includes infusing the thermoplastic member with a gas to form a gas-infused thermoplastic member and transmitting an energy beam onto the selected portion of the gas-infused thermoplastic member to induce subsurface heating of the selected portion of the gas-infused thermoplastic member to form microcellular bubbles within the selected portion of the gas-infused thermoplastic member.
B29C 44/34 - Moulage par pression interne engendrée dans la matière, p.ex. par gonflage ou par moussage - Eléments constitutifs, détails ou accessoires; Opérations auxiliaires
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Fujise, Ken
Pinkaew, Decha
Blagg, Brian
Serwetnyk, Michael
Brackett, Christopher M.
Zuo, Ang
Halim, Hasseri
Abrégé
Described herein is the development of ureas and thioureas as small molecular weight fortilin inhibitors. Small molecular weight compounds that inhibit fortilin, as well as compositions, and methods for using same, described herein ameliorate atherosclerosis by targeting fortilin, not hypercholesterolemia or lipid metabolism. This contrasts with the majority of anti-atherosclerosis therapies that rely on lipid lowering and modification. The data presented herein show that the inhibition of fortilin leads to the polarization of macrophages to the anti-inflammatory, anti-atherosclerotic, M2 phenotype. These inhibitors can be used to treat atherosclerosis as well as fortilin-associated cancers.
C07C 243/18 - Hydrazines ayant des atomes d'azote de groupes hydrazine liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant des cycles
C07C 335/16 - Dérivés de thiourée ayant des atomes d'azote de groupes thiourée liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné
The present disclosure provides a method of analyzing the structure of a glycan sample, the method including: receiving data indicative of one or more spectra of mass-to-charge ratio (m/z) versus relative abundance of the glycan sample from a mass spectrometer (MS) instrument; generating a ratio according to the following Equation:
The present disclosure provides a method of analyzing the structure of a glycan sample, the method including: receiving data indicative of one or more spectra of mass-to-charge ratio (m/z) versus relative abundance of the glycan sample from a mass spectrometer (MS) instrument; generating a ratio according to the following Equation:
a
a
+
b
The present disclosure provides a method of analyzing the structure of a glycan sample, the method including: receiving data indicative of one or more spectra of mass-to-charge ratio (m/z) versus relative abundance of the glycan sample from a mass spectrometer (MS) instrument; generating a ratio according to the following Equation:
a
a
+
b
wherein a is a magnitude of one or more first peaks in the one or more spectra and b is the magnitude of one or more second peaks in the one or more spectra; determining that the ratio is within a range of a predetermined ratio; based on determining that the ratio is within the range of the predetermined ratio, determining that a predetermined structural characteristic is present in the glycan sample; and outputting an indication of the predetermined structural characteristic in the glycan sample.
Seattle Children's Hospital d/b/a Seattle Children's Research Institute (USA)
Inventeur(s)
King, Daniel
Hannaford, Blake
Li, Yangming
Adidharma, Lingga
Bly, Randall
Abuzeid, Al-Waleed M.
Moe, Kristen S.
Abrégé
A method includes accessing training images that collectively depict multiple stages of a surgical procedure. The method also includes accessing labels that indicate, for each of the training images, characteristics of one or more surgical tools depicted and a stage of the multiple stages of the surgical procedure depicted. The method also includes training a computational model, using the training images and the labels, to associate runtime images with a stage of the multiple stages based on characteristics of one or more surgical tools that are depicted by the runtime images. Another method includes associating, using a computational model, runtime images with a stage of a surgical procedure based on characteristics of one or more surgical tools depicted by the runtime images and generating output that indicates the stage associated with each of the runtime images.
G06N 3/047 - Réseaux probabilistes ou stochastiques
G06N 3/088 - Apprentissage non supervisé, p.ex. apprentissage compétitif
G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 10/774 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source méthodes de Bootstrap, p.ex. "bagging” ou “boosting”
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G16H 70/20 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des pratiques ou des directives
29.
COMPOSITIONS INCLUDING ENDOPHYTES FOR IMPROVING PLANT NUTRITION, GROWTH,AND PERFORMANCE AND METHODS OF USING THE SAME
Endophyte inoculant compositions, methods of making such compositions, methods of using such compositions, and physiologically altered plants treating with such compositions are disclosed. The endophyte inoculant composition may include one or more of endophyte strains WW5, WW6, WW7, and PTD1, which promote plant mineral nutrient acquisition and uptake, vigor, health, growth, and yield when applied to non-native host plants.
Systems and methods of identifying medical disorders in one or more subjects are disclosed herein. In one embodiment, sound is transmitted toward a subject and at least a portion of the sound reflected by the subject and is acquired as echo data. The acquired echo data is used to generate a motion waveform having a plurality of peaks detected therein. At least a portion of the plurality of peaks may be indicative of movement of the subject. One or more medical disorders in the subject can be identified based on, for example, time durations and/or amplitude changes between peaks detected in the motion waveform.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
A61B 5/113 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre se produisant au cours de la respiration
31.
NANOPORE-BASED ANALYSIS OF PROTEIN CHARACTERISTICS
Methods for nanopore-based protein analysis are provided. The methods address the characterization of a target protein analyte, which has a dimension greater than an internal diameter of the nanopore tunnel, and which is also physically associated with a polymer. The methods further comprise applying an electrical potential to the nanopore system to cause the polymer to interact with the nanopore tunnel. The ion current through the nanopore is measured to provide a current pattern reflective of the structure of the portion of the polymer interacting with the nanopore tunnel. This is used as a metric for characterizing the associated protein that does not pass through the nanopore.
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
32.
De Novo Design of Potent and Selective Interleukin Mimetics
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Silva Manzano, Daniel Adriano
Yu, Shawn
Ulge, Umut
Baker, David
Garcia, Kenan Christopher
Spangler, Jamie
Walkey, Carl
Rubio, Alfredo Quijano
Jude, Kevin
Weitzner, Brian
Abrégé
De novo designed polypeptides that bind to IL-2 receptor βγc heterodimer (IL-2Rβγc), IL-4 receptor αγc heterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
The present disclosure provides a device comprising a catheter having a first end and a second end opposite the first end. The catheter includes a first lumen, a second lumen, and a third lumen. The first lumen is configured to receive a guidewire therethrough to position the device in a desired anatomy. The device includes a needle movably positioned within the second lumen of the catheter. The needle includes a first end and a second end opposite the first end, and the needle is hollow such that the needle includes a lumen extending from the first end to the second end. The needle is configured to transition from a first position in which the first end of the needle is positioned entirely within the second lumen of the catheter to a second position in which the first end of the needle extends out of the second lumen of the catheter.
A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
A61M 25/06 - Aiguilles avec un guide pour piquer le corps ou analogues
A61F 2/958 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes ballons gonflables pour insérer les stents ou les endoprothèses déployables couvertes
A61M 25/08 - Moyens pour faire avancer le cathéter ou la sonde, p.ex. autopropulsés
34.
SYSTEMS AND METHODS FOR MEDIATED-REALITY SURGICAL VISUALIZATION
The present technology relates generally to systems and methods for mediated-reality surgical visualization. A mediated-reality surgical visualization system includes an opaque, head-mounted display assembly comprising a frame configured to be mounted to a user's head, an image capture device coupled to the frame, and a display device coupled to the frame, the display device configured to display an image towards the user. A computing device in communication with the display device and the image capture device is configured to receive image data from the image capture device and present an image from the image data via the display device.
H04N 13/344 - Affichage pour le visionnement à l’aide de lunettes spéciales ou de visiocasques avec des visiocasques portant des affichages gauche et droit
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
A61B 1/05 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision caractérisés par le fait que le capteur d'images, p.ex. l'appareil photographique, est placé dans la partie de l'extrémité distale
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p.ex. pour le traitement de la luxation ou pour la protection de bords de blessures
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
G06F 3/14 - Sortie numérique vers un dispositif de visualisation
H04N 13/239 - Générateurs de signaux d’images utilisant des caméras à images stéréoscopiques utilisant deux capteurs d’images 2D dont la position relative est égale ou en correspondance à l’intervalle oculaire
35.
BIOPLASTIC MATERIALS OBTAINED FROM BIOLOGICAL MATTER
Bioplastic compositions and methods of making are described herein. The various mechanical and physical properties of the bioplastic may be varied by altering the thermoforming or incorporating an additive depending on the desired mechanical and physical properties of the end product. The bioplastic may be made entirely of biomatter and be backyard compostable.
A biological cement including algal biomatter, cement, and water. The present disclosure also provides methods of preparing the biological cement. The biological cement can be used in place of traditional cement, for instance by being incorporated into mortar or concrete for structural or other applications. The algal biomatter may include one or more of biomass from Chlorella, Spirulina (Arthrospira platensis), Saccharina latissima, Ulva spp. (such as U. lactuca or U. expensa), Agarophyton, Sargassum, Gracilaria parvispora, Halymenia hawaiiana or Caulerpa lentillifera.
C04B 28/14 - Compositions pour mortiers, béton ou pierre artificielle, contenant des liants inorganiques ou contenant le produit de réaction d'un liant inorganique et d'un liant organique, p.ex. contenant des ciments de polycarboxylates contenant des ciments de sulfate de calcium
C04B 40/02 - Choix de l'environnement pour le durcissement
C12N 11/04 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique piégées à l’intérieur du support, p.ex. dans un gel ou dans des fibres creuses
C12N 11/084 - Polymères comportant des unités alcool vinyliques
T. pallidumT. pallidumT. pallidumT. pallidum is present in the sample. The disclosed elements can be used for clinical tests to determine whether the patient has syphilis as the basis for further clinical testing or treatment of syphilis.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
39.
DEVICES, SYSTEMS, AND METHODS FOR PERSONALIZED DOSIMETRY
Various devices, systems, and methods for performing personalized dosimetry of a patient receiving a radiopharmaceutical are described. In an example method, anatomic data is generated by performing a computed tomography (CT) scan on the patient when they are lying down and wearing a garment. Based on the anatomic data, locations of organs of the patient are determined with respect to one or more fiducial markers integrated with the garment. Detectors for detecting photons from a radiopharmaceutical are placed on the garment based on locations of the organs. Subsequently, the patient may be administered a dose of the radiopharmaceutical. When the patient wears the garment, the detectors may detect photons released from the decaying radiopharmaceutical that is distributed in the organs. The radiation dosage to the organs may be determined based on the detected photons.
The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
Compositions and methods for modular fabrication of large, three-dimensional, perfusable networks of vascularized tissue are provided. Each layer within the tissue may include the same or different cell types and have the same or different types of vasculature. In some aspects layers of tissue together form the large, three-dimensional perfusable networks as each layer contains a portion of the larger tissue and the combination of the various layers creates a tertiary structure of integrated perfusable networks that exhibit remodeling and evenly distributed perfusion among layers while maintaining a patterned open-lumen architecture.
Embodiments of the present disclosure provide compositions and methods for injectable recombinant protein-based hydrogels for therapeutic delivery. Embodiments of the composition and methods comprise a recombinant protein, a cell consortia, and a biocompatible medium. The recombinant protein comprises one or more self-association domains and a flexible linker comprising a pseudorepeat of amino acids, forming stable hydrogels in contact with the cell consortia. Such composition and methods have broad application in delivery of viable cells to a biological tissue for tissue repair and regeneration.
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
43.
CELL-FREE DNA SEQUENCE DATA ANALYSIS TECHNIQUES FOR ESTIMATING FETAL FRACTION AND PREDICTING PREECLAMPSIA
In some embodiments, a computer-implemented method of enhancing sequence read data from a cell-free DNA (cfDNA) sample from a subject for predicting a pregnancy-related condition is provided. A computing system determines a coverage profile based on sequence read data for a plurality of informative sites associated with specific tissue types, cell types, or cell states. The computing system generates a prediction of a presence of or an absence of the pregnancy-related condition by providing at least features from a set of features based on a predicted fetal fraction and a set of features based on the coverage profile as input to at least one machine learning model trained to predict a probability of future onset of the pregnancy-related condition based on the features. In some embodiments, a computer-implemented method of enhancing sequence read data for predicting fetal fraction is provided.
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16B 40/00 - TIC spécialement adaptées aux biostatistiques; TIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p.ex. extraction de connaissances ou détection de motifs
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
44.
FUNCTIONALIZED CHROMOPHORIC POLYMER DOTS AND BIOCONJUGATES THEREOF
The present invention provides, among other aspects, functionalized chromophoric polymer dots comprising a hydrophobic core and a hydrophilic cap, and bioconjugates thereof. Also provided are improved methods for preparing functionalized chromophoric polymer dots. Methods for in vivo imaging and molecular labeling are also disclosed.
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
A nanoparticle for delivery of mRNA to cell, comprising a core comprising a polyethylenimine polymer having fluorinated groups covalently coupled thereto and with mRNA reversibly associated therewith, and a shell surrounding the core comprising heparin. Ij some embodiments, the nanoparticle comprises a targeting agent associated with the shell, wherein the targeting agent is selected from the group consisting of agents that bind to receptors overexpressed on tumor cells, agents that bind to cell surf ace antigens that are expressed on pluripotent stem cells, agents that bind to cell surface antigens on T cells, and agents that bind to antigens presented by MHO molecules. Pharmaceutical compositions that include the nanoparticle and methods for using the nanoparticle for transfecting cells are provided
C08G 69/48 - Polymères modifiés par post-traitement chimique
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation utilisant la micro-encapsulation, p.ex. utilisant des vésicules liposomiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/67 - Méthodes générales pour favoriser l'expression
Disclosed herein are ceramic selective membranes and methods of forming the ceramic selective membranes by forming a selective silica ceramic on a porous membrane substrate.
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
B01D 39/20 - Autres substances filtrantes autoportantes en substance inorganique, p.ex. papier d'amiante ou substance filtrante métallique faite de fils métalliques non-tissés
H01M 8/1053 - Composites ou mélanges à électrolyte polymère constitués de couches de polymères dont au moins une couche est conductrice ionique
H01M 8/1062 - Matériaux d’électrolyte polymère caractérisés par un support poreux n’ayant pas de propriétés conductrices ioniques caractérisés par les propriétés physiques du support poreux, p.ex. sa porosité ou son épaisseur
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétés; Procédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
H01M 8/106 - Matériaux d’électrolyte polymère caractérisés par un support poreux n’ayant pas de propriétés conductrices ioniques caractérisés par la composition chimique du support poreux
H01M 8/1016 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides caractérisés par le matériau d’électrolyte
H01M 8/18 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible à régénération, p.ex. batteries à flux REDOX ou éléments à combustible secondaires
B01D 69/10 - Membranes sur support; Supports pour membranes
Apparatuses and methods for measuring total blood volume with ultrasound are disclosed. In one embodiment, a system for monitoring a blood volume of a patient includes an ultrasound transmitter configured for emitting an ultrasound toward a target blood vessel of the patient; and an ultrasound receiver configured for receiving the ultrasound reflected from the target blood vessel of the patient. The system also includes, a controller configured for: determining an expanded state of the blood vessel based on the ultrasound reflected from the target blood vessel; determining a collapsed stated of the blood vessel based on the ultrasound reflected from the target blood vessel; and determining the blood volume of the patient based on the ratio of the collapsed stated and the expanded stated of the blood vessel.
In some embodiments, a molecular tagging system that uses synthetic DNA-based tags is provided. In some embodiments, a kit for tagging objects with molecular tags is provided that comprises a plurality of molbit reservoirs. Each molbit reservoir is associated with a molbit and includes nucleic acid molecules that represent the molbit. In some embodiments, a method is provided wherein a digital tag value is determined, the digital tag value is converted to a molbit tag value, nucleic acid molecules associated with each molbit value indicated as present in the molbit tag value are combined, and the combined nucleic acid molecules are applied to an object to tag the object. In some embodiments, a system is provided that includes a computing system configured to receive raw nanopore signals from a sequencing device, to identify molbits based on the signals, and to determine a digital tag based on the identified molbits.
The technology as described herein relates to discovery of methods for generating odontoblasts or organoids thereof in vitro and compositions that utilize the generated odontoblasts for restoringtooth structure.
Overexpressed proteins associated with inflammatory adipocytes have been demonstrated in TNF-a inflamed adipocyte lines derived from humans and mice as well as in visceral fat derived from mice fed an inflammatory-generating high fat high sucrose diet. The adipocyte-associated proteins are immunogenic in humans and mice, and can be used as a vaccine that drives Type II T-cells to inflammatory adipose tissue. Compositions and methods for the prevention and treatment of disease associated with metabolic obesity, including cancer, such as breast cancer, and non-alcoholic fatty liver disease (NAFLD) are provided.
Systems and methods to link CD40 signaling to antigen binding, independently of CD40 ligand binding are described. The systems and methods include fusion proteins including an extracellular antigen binding domain linked to an intracellular CD40 signaling domain.
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
C07K 16/12 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61P 41/00 - Médicaments utilisés en chirurgie, p.ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
The present disclosure provides methods, systems, and kits for quantifying lipoprotein(a) based on measuring selected proteotypic peptide(s). The methods of the disclosure are also useful in determining if a subject is at risk to develop cardiovascular disease. The disclosure also provides methods of determining a reference amount of selected proteotypic peptide(s) in a reference sample.
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
54.
MODULAR KINETICALLY-CONTROLLED FUNCTIONAL RNA CONSTRUCTS AND RELATED COMPOSITIONS, SYSTEMS, AND METHODS
Disclosed are kinetically-controlled RNA biosensor constructs and related, nucleic acids, vectors, cells, systems and methods useful for detecting ligands of interest. Also disclosed are computer implemented methods for designing kinetically-controlled biosensors, guide RNA molecules, and/or target promoter sequences, and constructs produced thereby. Exemplary embodiments include scRNAs and expression cassettes incorporating synthetic promoters for implementation of CRISPRa.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/542 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec inhibition stérique ou modification du signal, p.ex. extinction de fluorescence
G01N 33/94 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des narcotiques
55.
PROTEIN-BASED COMPOSITION FOR ADDITIVE MANUFACTURING
Universidad del Pais Vasco/Euskal Herriko Unibersitatea (Espagne)
Inventeur(s)
Nelson, Alshakim
Sánchez Rexach, Eva
Sardon, Haritz
Abrégé
Disclosed herein are compositions comprising globular proteins and diacrylate-containing compounds that can react in-situ to provide polymerized networks that can be formed into objects using additive manufacturing techniques, such as printing techniques that use vat photopolymerization. Objects printed using the disclosed compositions also are described, with embodiments of such objects exhibiting shape recovery behavior. Also disclosed are methods of making and using the disclosed compositions.
C09D 4/00 - Compositions de revêtement, p.ex. peintures, vernis ou vernis-laques, à base de composés non macromoléculaires organiques ayant au moins une liaison non saturée carbone-carbone polymérisable
C09D 189/00 - Compositions de revêtement à base de protéines; Compositions de revêtement à base de leurs dérivés
Materials, methods, and systems for biorthogonal ligation of hydrogel labels to crosslinked-natural polymer hydrogels are provided. A heterobifunctional linker includes a peptide-reactive activated functional group on the heterobifunctional linker, including an activated amine-reactive functional group, an activated thiol-reactive functional group and being reactive with a hydrogel comprising a crosslinked natural polymer. The heterobifunctional linker also includes a photocaged reactive group including a photocaged hydroxylamine, a photocaged alkoxyamine, a photocaged hydrazide, a photocaged amine, a photocaged tetrazine, or a photocaged alkyne-containing moiety. The peptide-reactive activated functional group does not include an azide.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C07D 207/46 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec les hétéro-atomes liés directement à l'atome d'azote du cycle
57.
WETTING AND FRACTURE INDUCED COMPOSITES FOR HIGHLY SENSITIVE RESISTIVE AND CAPACITIVE SENSORS
A sensor, comprising including a composite substrate including a template material, where the template material includes a plurality of insulating fibers, and a plurality of carbon nanotubes bonded to the insulating fibers forming a nanotube coating on the insulating fibers, and where the composite substrate exhibits a tensional fracture induced by a unidirectional tensile force to the composite substrate, wherein the plurality of insulating fibers align along the tensile force and expand in an out-of-plane direction at the site of the fracture, a first electrode coupled to the nanotube coating on one side of the fracture, and a second electrode coupled to the nanotube coating on the opposite side of the fracture, such that an electrical signal applied between the first electrode and the second electrode passes through the plurality of junctions at the site of the fracture.
A61B 5/263 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet caractérisées par les matériaux des électrodes
D21H 17/67 - Composés insolubles dans l'eau, p.ex. charges ou pigments
D21H 21/14 - Matériaux non fibreux ajoutés à la pâte, caractérisés par leur fonction, leur forme ou leurs propriétés; Matériaux d'imprégnation ou de revêtement du papier, caractérisés par leur fonction, leur forme ou leurs propriétés caractérisés par leur fonction ou leurs propriétés dans, ou sur, le papier
D21H 27/00 - Papier particulier non prévu ailleurs, p.ex. obtenu par des procédés multi-étapes
D21H 19/68 - Couches caractérisées par un effet visuel particulier, p.ex. avec des dessins ou texturées inégales, rompues ou discontinues
D06M 11/74 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexes; Un tel traitement combiné avec un traitement mécanique, p.ex. mercerisage avec du carbone ou ses composés avec des acides graphitiques ou leurs sels
D06M 23/16 - Procédés pour l'application non uniforme d'agents traitants, p.ex. traitement sur une seule face; Traitement différentiel
D06M 11/05 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexes; Un tel traitement combiné avec un traitement mécanique, p.ex. mercerisage avec des boranes, des diboranes, des silanes, des disilanes, des phosphines, des diphosphines, des stibines, des distibines, des arsines ou des diarsines, ou leurs complexes avec de l'eau lourde
G01L 1/18 - Mesure des forces ou des contraintes, en général en utilisant des propriétés des matériaux piézo-résistants, c. à d. des matériaux dont la résistance ohmique varie suivant les modifications de la grandeur ou de la direction de la force appliquée au matériau
G01L 1/14 - Mesure des forces ou des contraintes, en général en mesurant les variations de la capacité ou de l'inductance des éléments électriques, p.ex. en mesurant les variations de fréquence des oscillateurs électriques
58.
POLYMER-SILICA HYBRID PDOTS AND METHODS OF USE THEREOF
The present disclosure provides organic-inorganic hybrid polymer particles, which have desirable surface chemistry and optical properties that make them particularly suitable for biological and optical applications. The present disclosure also provides methods of making organic-inorganic hybrid polymer particles. The present disclosure also provides methods of using the organic-inorganic hybrid polymer particles for biological and optical applications.
H01B 1/18 - Matériau conducteur dispersé dans un matériau inorganique non conducteur le matériau conducteur comportant des compositions à base de carbone-silicium, du carbone ou du silicium
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
G02F 1/015 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des éléments à semi-conducteurs ayant au moins une barrière de potentiel, p.ex. jonction PN, PIN
59.
BARCODED INFLUENZA VIRUSES AND DEEP MUTATIONAL SCANNING LIBRARIES INCLUDING THE SAME
Methods to create barcoded influenza viruses without disrupting the function of the viral proteins and the proper packaging of the viral genome segments are described. The barcoded influenza viruses can be used within deep mutational scanning libraries to map influenza resistance mutations to therapeutic treatments. The libraries can also be used to predict influenza strains that may become resistant to therapeutic treatments and/or more easily evolve to infect new species. The libraries include features that allow efficient collection and assessment of informative data, obviating bottlenecks of previous approaches.
ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOMATERIALES - CIC BIOMAGUNE (Espagne)
UNIVERSITY OF THE BASQUE COUNTRY, UPV/EHU (Espagne)
Inventeur(s)
Nelson, Alshakim
Sánchez Rexach, Eva
Sadaba, Naroa
Yu, Siwei
Sardón Muguruza, Haritz
De Aberasturi, Dorleta Jiménez
Liz-Marzan, Luis Manuel
Abrégé
Shape-restoring materials, as well as techniques for generating shape-restoring materials, are described. An example method includes generating a construct by exposing, to UV-visible light, a resin comprising a globular protein, a water-soluble co-monomer, light-to-heat converting nanoparticles, water, and a photoinitiator. At least a portion of the water is removed from the construct. The construct is converted from a first shape to a second shape by applying a force to the construct. The construct is reverted to the first shape in response to being exposed to NIR light, due to the absorption of the NIR light by the nanoparticles.
The present disclosure is directed to relates to systems and methods for evaluating tissue using high intensity focused ultrasound (HIFU) energy. In one embodiment, for example, a system for treating a patient comprises an ultrasound source configured to deliver HIFU energy to a target tissue mass of the patient and a function generator operably coupled to the ultrasound source for initiating a pulsing protocol for delivering the HIFU energy. The system further comprises a controller configured to perform operations comprising applying HIFU energy to induce cavitation in the target tissue mass and cause a biomarker to be released, comparing a baseline concentration of the biomarker from a first fluid sample to a concentration of the biomarker in a second fluid sample within 2 hours after applying HIFU, and repeating the applying and comparing until the concentration of the biomarker in the fluid sample falls below a threshold value.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
A61B 8/08 - Détection de mouvements ou de changements organiques, p.ex. tumeurs, kystes, gonflements
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61B 5/15 - Dispositifs de prélèvement d'échantillons de sang
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
Methods and kits for assessing and partially or uniquely identifying proteins, such as in complex mixtures of proteins and other molecules/structures, are described. In an embodiment, the methods include combinatorially barcoding target amino acid residues on the protein and, in certain embodiments, enzymatically cleaving the protein, such as before and after rounds of combinatorial barcoding. In an embodiment, the methods include (a) attaching a first nucleic acid molecule to target amino acid residues in the plurality of proteins in the sample to provide nascent nucleic acid tags at the target amino acid residues; (b) performing one or more rounds of split-pool barcoding to provide mature nucleic acid tags at the target amino acid residues (c) sequencing the mature nucleic acid tags; and (d) determining a frequency of the target amino acid residues in one or more protein of the plurality of proteins.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
63.
Glycoengineered protein nanoparticles and uses thereof
Polypeptides including the amino acid sequence of SEQ ID NO:78-80, substituted with one or more sequon, are provided, as are fusion proteins and nanoparticles formed from such polypeptides, and methods for their use.
Methods and systems for creating patterns in tissue growth for tissue engineering are disclosed. In one embodiment, a method for arranging biological cells along predetermined patterns using an ultrasound includes: emitting the ultrasound by an ultrasound transducer; transmitting the ultrasound through a holographic lens toward a plurality of cells; and generating a pressure field in the predetermined patterns. The predetermined pattern includes a plurality of mutually parallel transverse planes. The parallel transverse planes are configured to entrap groups of cells of the plurality of cells. The axial pressure gradients within the parallel transverse planes are smaller than a first predetermined threshold. The lateral pressure gradients within the parallel transverse planes are larger than a second predetermined threshold. In response to generating the pressure field, the groups of entrapped cells are aligned within parallel transverse planes.
An edge device can include a processing device, an image sensor, and a memory having instructions that are executable by the processing device for causing the processing device to perform operations. The processing device can receive, from the image sensor, an image of an environment. The processing device can determine a visibility measure corresponding to the environment by determining a dark channel of the image, determining, based on the dark channel of the image, a transmission map of the image, and determining, based on the transmission map, a visual contrast of the image. The processing device can generate information corresponding to the visibility measure.
G06V 10/56 - Extraction de caractéristiques d’images ou de vidéos relative à la couleur
G06T 7/90 - Détermination de caractéristiques de couleur
G06V 10/60 - Extraction de caractéristiques d’images ou de vidéos relative aux propriétés luminescentes, p.ex. utilisant un modèle de réflectance ou d’éclairage
A ram accelerator for accelerating a projectile is provided. The ram accelerator includes a first tube body having a first projectile bore, a second tube body having a second projectile bore axially aligned with the first projectile bore, and a baffle positioned between and operably coupling the first and second tube bodies. The baffle can have an annular baffle wall defining a central bore that is axially aligned with the first and second projectile bores, and a chamber arranged adjacent to the annular baffle wall. The chamber can extend radially outward from the central bore and the annular baffle wall can be configured to sweep a combustion wave relative to the projectile to prevent the combustion wave from traveling ahead of the projectile, leading to an unstart mechanism of the projectile in the ram accelerator.
F41A 1/02 - Propulsion de projectiles en survitesse utilisant des moyens successifs pour augmenter la force propulsive, p.ex. utilisant la combustion de plusieurs charges propulsives, allumées l'une après l'autre et disposées le long du tube de l'arme; Propulsion multi-étages de projectiles
67.
USE OF A DOUBLE-STRANDED DNA CYTOSINE DEAMINASE FOR MAPPING DNA-PROTEIN INTERACTIONS
The disclosure provides methods and related compositions and kits for mapping DNA-protein interactions (DPIs). In one aspect, the disclosed methods comprise contacting a double stranded DNA molecule with a target protein; coupling a double stranded DNA deaminase (DddA) to the target protein, before or after the contacting step; permitting deamination of one or more cytosine residues in a domain of the double stranded DNA molecule by the DddA to provide one or more uracil residues, wherein the domain comprises a site of interaction between the target protein and the double stranded DNA molecule; determining the sequence of at least a portion of the double stranded DNA molecule; and detecting the domain comprising one or more cytosine deamination events. The method can be controlled by use of DddA inhibitors. The method can also incorporate use of inhibiting a base-excision repair pathway when addressing DPIs in a cellular context.
Systems and methods for analyzing particles flowing in a channel are described. In an embodiment, the channel is configured to flow a particle through a lumen of the channel, the channel defining an interrogation window configured to allow light to pass into and out of the lumen; a light engine comprising: a first light source positioned to output first excitation light onto a first portion of the channel in the interrogation window; and a second light source positioned to output second excitation light onto a second portion of the channel in the interrogation window separate from the first portion. In an embodiment, the systems include an emission fiber bundle comprising a first emission optical fiber and a second emission optical fiber, wherein a proximal end of first emission optical fiber and second emission optical fiber are arranged in an emission fiber bundle head.
Disclosed are polypeptides having an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of the amino acid sequences listed in Tables 1, 2, and 3, and heteropolymers formed from such polypeptides.
Endophyte inoculant compositions, methods of making such compositions, methods of using such compositions, and physiologically altered plants treating with such compositions are disclosed. The endophyte inoculant composition may include one or more of endophyte strains WW5, WW6, WW7, and PTD1, which promote plant mineral nutrient acquisition and uptake, vigor, health, growth, and yield when applied to non-native host plants.
A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
Nanoporous selective sol-gel ceramic membranes, selective-membrane structures, and related methods are described. Representative ceramic selective membranes include ion-conductive membranes (e.g., proton-conducting membranes) and gas selective membranes. Representative uses for the membranes include incorporation into fuel cells and redox flow batteries (RFB) as ion-conducting membranes.
C04B 35/14 - Produits céramiques mis en forme, caractérisés par leur composition; Compositions céramiques; Traitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base d'oxydes à base de silice
C04B 35/10 - Produits céramiques mis en forme, caractérisés par leur composition; Compositions céramiques; Traitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base d'oxydes à base d'oxyde d'aluminium
C04B 35/48 - Produits céramiques mis en forme, caractérisés par leur composition; Compositions céramiques; Traitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base d'oxydes à base d'oxydes de zirconium ou d'hafnium ou de zirconates ou d'hafnates
B01D 71/28 - Polymères de composés vinylaromatiques
B01D 71/82 - Matériaux macromoléculaires non prévus spécifiquement dans un seul des groupes caractérisés par la présence de groupes déterminés, p.ex. introduits par un post-traitement chimique
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétés; Procédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
B01D 69/10 - Membranes sur support; Supports pour membranes
Disclosed herein is a generalizable and intuitive strategy to photomodulate biomaterials in full 3D non-discrete patterns across cellular scales through grayscale image z-stack-guided multiphoton optical-lithography (GIZMO). In one aspect a method for optical patterning of a material is presented with the method comprising of initializing a laser, wherein the laser is focused through an objective that is movable in the x, y, and z directions; wherein a laser intensity is modulated while in motion or progress throughout a raster scanning.
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en général; Appareils appropriés
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
Aspects of this disclosure describe a test strip that may include a sample input, assay circuitry, signaling circuitry, impedance circuitry, and/or energy harvesting circuitry. The sample input may be configured to receive a sample, such as a fluid sample. The assay circuitry of the test strip may be configured to perform an assay on at least a portion of the fluid sample. The signaling circuitry of the test strip may be configured to provide a modulated signal based on an output of the assay. The impedance circuitry of the test strip may be configured to present impedance changes to a touchscreen of an electronic device in accordance with the modulated signal. The test strip can then communicate data of the output of the assay (e.g., test results) to the electronic device using the touchscreen of the electronic device.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une oxydoréductase
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
G06F 3/041 - Numériseurs, p.ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction
G06F 3/044 - Numériseurs, p.ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction par des moyens capacitifs
74.
SCALABLE, SUBMICRON-RESOLUTION REPLICATION OF DNA ARRAYS
Systems, devices, kits, and methods for generating sequencing libraries for detecting low-frequency variants, and for distinguishing low-frequency biological variants from low-frequency technical variants, with duplex sequencing. Methods include introducing multiple levels of indices to cellular nucleic acid molecules of cells of a biological sample to enable differentiation of a cell from other cells of the sample, differentiation of a double-stranded cellular nucleic acid molecule from others of the cell, and differentiation of the individual strands of the double-stranded cellular nucleic acid molecule. Technical variants introduced during the workflow are identified as such due to their occurrence in only one family of duplex strands of the sequencing library, and biological variants are detected due to their occurrence in both families of duplex strands of the sequencing library. Detected biological variants can be linked with a particular cell of the biological sample in a high-throughput manner.
A method includes accessing training images and labels, where the training images depict fluorescence from samples and the labels indicate pH levels of the samples. The method also includes training a computational model, using the training images and the labels, to determine pH levels on tissue inside of a patient's mouth depicted by captured images. Another method includes generating one or more images of tissue inside of a patient's mouth, where the one or more images depict fluorescence from the tissue. The method also includes determining a pH level on the tissue using a model and pixel intensities of the one or more images, and generating an indication of the pH level on the tissue.
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p.ex. utilisation de bandes de papier indicateur
G01N 33/84 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des composés inorganiques ou le pH
Techniques for treating acute ischemic stroke, and other neurological pathologies, are described herein. An example method includes identifying a portion of a brain including overactive neurons and outputting an electrical signal to at least one stimulation electrode disposed away from the portion of the brain by a distance in a range of about 0.5 mm to 1 cm. The electrical signal includes a low-frequency component including bursts having a frequency in a range of about 2 Hz to about 10 Hz. The electrical signal includes a high-frequency component comprising pulses having a frequency in a range of about 200 Hz to about 2 kHz.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
78.
PRECISE GENOME DELETION AND REPLACEMENT METHOD BASED ON PRIME EDITING
Disclosed are methods and related compositions for genomic editing. In one aspect, methods of editing double stranded DNA (dsDNA) use first and second editing complexes specific for first and second target sequences on the sense and antisense strands of the dsDNA molecule, respectively. Each editing complex comprises an extended guide RNA associated with a fusion editor protein, which comprises a functional nickase domain and a functional reverse transcriptase domain. The respective guide RNAs guide their associated fusion editor proteins to the dsDNA, which implement single stranded breaks on opposite strands of the dsDNA. The respective reverse transcriptase domains generate 3′ overhangs. Repair of the dsDNA excises the portion of dsDNA disposed between the two single-stranded breaks. A variety of configurations and applications of the method are disclosed, providing flexible, facile, efficient, and precise methods to impose genetic manipulations.
A modular expansion joint (e.g., for a bridge) can include an upper expansion support exhibiting a hinge design arranged for pivoting about a vertically extending axis. The upper expansion support underneath may be accompanied by a moisture seal and/or a lower expansion support. The modular expansion joint may include two beams that may be spaced apart by a gap into which the upper expansion support etc. can be received. Each of the two beams can include a top flange defining a top surface and a web extending from the flange. The upper expansion support can be positioned between the top flanges, while the lower expansion support can be positioned between the webs, for example. The upper expansion support may provide a continuation of a travel surface across the beam tops and may accordingly reduce pressure spikes and/or noise from tires moving across the travel surface.
Polypeptide are providing that are at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-37, cyclic homo-oligomers of the polypeptides, and uses thereof.
Polypeptides that comprise axle or ring components of protein nanomachines, and kits and nanomachines including such polypeptides are disclosed herein.
BIO-IMPEDANCE SENSING FOR GESTURE INPUT, OBJECT RECOGNITION, INTERACTION WITH PASSIVE USER INTERFACES, AND/OR USER IDENTIFICAITON AND/OR AUTHENTICATION
This disclosure describes systems, apparatuses, and methods that utilize electric field sensing in an antenna topology. In some embodiments, the systems, apparatuses, and methods use a sensing modality, such as bio-impedance sensing, to detect and/or determine one or more user activities. The bio-impedance sensing can be used for held-object or touched- object recognition, gesture input recognition (e g., recognition of one-handed gestures, two- handed gestures, etc.), user interface (UI) interaction by utilizing electrically passive components, and/or biometric identification and/or authentication.
A61B 5/0507 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio utilisant des micro-ondes ou des ondes térahertz
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
G06F 3/046 - Numériseurs, p.ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction par des moyens électromagnétiques
G01S 13/89 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques pour la cartographie ou la représentation
A61B 5/053 - Mesure de l'impédance ou de la conductivité électrique d'une partie du corps
Seattle Children's Hospital dba Seattle Children's Research Institute (USA)
University of Washington (USA)
Inventeur(s)
Zhao, Yongdong
Scheck, Joshua
Partridge, Savannah Corrina
Iyer, Ramesh S.
Thapa, Mahesh
Biswas, Sr., Debosmita
Bhide, Nivrutti Vasudev
Cain, Kevin Charles
Pyke, Jason Michael
Abrégé
A method for determining a presence of arthritis in a patient, including obtaining a first image of a patient's joint, wherein the first image is a visible light image, obtaining a second image of the patient's joint, wherein the second image is a thermal light image, determining an outline of the patient's joint from the first image, determining an outline of a reference area from the first image, wherein the patient's joint is adjacent to the reference area, determining a first representative topological temperature within the outline of the patient's joint of the first image from the second image, determining a second representative topological temperature within the outline of the reference area of the first image from the second image, comparing the first representative topological temperature and the second representative topological temperature; and determining a likelihood of the presence of arthritis within the patient's joint.
H04N 23/23 - Caméras ou modules de caméras comprenant des capteurs d'images électroniques; Leur commande pour générer des signaux d'image uniquement à partir d'un rayonnement infrarouge à partir du rayonnement infrarouge thermique
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Systems and methods for capturing and rendering light fields for head-mounted displays are disclosed. A mediated-reality visualization system includes a head-mounted display assembly comprising a frame configured to be mounted to a user's head and a display device coupled to the frame. An imaging assembly separate and spaced apart from the head-mounted display assembly is configured to capture light-field data. A computing device in communication with the imaging assembly and the display device is configured to receive light-field data from the imaging assembly and render one or more virtual cameras. Images from the one or more virtual cameras are presented to a user via the display device.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
H04N 13/254 - Générateurs de signaux d’images utilisant des caméras à images stéréoscopiques en combinaison avec des sources de rayonnement électromagnétique pour l’éclairage du sujet
H04N 13/344 - Affichage pour le visionnement à l’aide de lunettes spéciales ou de visiocasques avec des visiocasques portant des affichages gauche et droit
H04N 13/243 - Générateurs de signaux d’images utilisant des caméras à images stéréoscopiques utilisant au moins trois capteurs d’images 2D
H04N 13/282 - Générateurs de signaux d’images pour la génération de signaux d’images correspondant à au moins trois points de vue géométriques, p.ex. systèmes multi-vues
De novo designed proteins with binding activity are disclosed, which were designed starting from a desired functional site and jointly filling in the missing sequence and structure needed to complete the protein, and uses of the binding proteins.
In some embodiments, a computer-implemented method of predicting a molecule type using segment read information is provided. A computing device receives a segment read for a molecule. The computing device determines one or more k-mers for the segment read. For each k-mer of the one or more k-mers, the computing device retrieves one or more records from a hash table using the k-mer as a key, wherein each record includes an identifier associated with a molecule type. The computing device generates a molecule type prediction for the segment read based on the identifiers of the retrieved one or more records.
G16B 50/00 - TIC pour la programmation d’outils ou de systèmes de bases de données spécialement adaptées à la bio-informatique
G16B 50/30 - Entreposage de données; Architectures informatiques
G16B 40/00 - TIC spécialement adaptées aux biostatistiques; TIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p.ex. extraction de connaissances ou détection de motifs
G06F 16/13 - Structures d’accès aux fichiers, p.ex. indices distribués
G06F 16/00 - Recherche d’informations; Structures de bases de données à cet effet; Structures de systèmes de fichiers à cet effet
A method includes irradiating, via a heating element, a first portion of a workpiece with electromagnetic radiation having an oscillation frequency within a range of 1 MHz to 300 MHz, thereby heating the first portion of the workpiece. The method also includes applying a pressure to the first portion of the workpiece via an actuator and making a determination that a condition of the first portion or the actuator satisfies one or more criteria. The method also includes moving the workpiece and/or the actuator, in response to making the determination, such that a second portion of the workpiece is aligned with the actuator. A system includes one or more processors, an infrared camera, an actuator, a platform, a motor, a power source, a load cell, and a computer readable medium storing instructions that, when executed by the one or more processors, cause the system to perform the method.
B29C 65/04 - Chauffage diélectrique, p.ex. soudage par haute fréquence
B29C 65/14 - Assemblage d'éléments préformés; Appareils à cet effet par chauffage, avec ou sans pressage par énergie ondulatoire ou rayonnement corpusculaire
B29C 65/34 - Assemblage d'éléments préformés; Appareils à cet effet par chauffage, avec ou sans pressage avec des éléments chauffés qui restent dans le joint, p.ex. un "élément de soudage perdu"
89.
DRUG-LIKE MOLECULES AND METHODS FOR THE THERAPEUTIC TARGETING OF MICRORNA-21
Compounds and compositions for inhibiting miR-21, methods for inhibiting miR-21 in a subject, and methods for treating a disease or condition treatable by decreasing the level of microRNA miR-21 in a subject.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
Methods and systems for bonding of structures using high intensity focused ultrasound are disclosed. In one embodiment, a method for assembling components using ultrasound includes: positioning a first part of an assembly with respect to a second part of the assembly; heating a region of the assembly by focusing the ultrasound from an ultrasound transducer to the region of the assembly; and, in response to heating the region of the assembly, bonding the first part of the assembly to the second part of the assembly.
B32B 37/12 - Procédés ou dispositifs pour la stratification, p.ex. par polymérisation ou par liaison à l'aide d'ultrasons caractérisés par l'usage d'adhésifs
B29C 65/08 - Assemblage d'éléments préformés; Appareils à cet effet par chauffage, avec ou sans pressage avec des vibrations ultrasonores
91.
INTEGRATED CAVITY ACOUSTO-OPTICS FOR FREQUENCY DOMAIN OPTICAL COMPUTING AND FREQUENCY COMB GENERATION
Systems and methods for optical computation and acousto-optic modulation are described. The systems and methods comprise acousto-optic modulators with reflectors and transducers used for actuation and modulation of mechanical waves. The systems further comprise multilayer optical computing systems incorporating arrays of acousto-optic modulators. In an embodiment, the acousto-optic modulator comprises a substrate; an optical layer coupled to a first portion of the substrate, the optical layer comprising: a free-standing portion shaped and positioned to define a gap between the free-standing portion of the optical layer and the substrate; and a rib waveguide comprising a photonic crystal, formed in the free-standing portion; and a piezoelectric transducer mechanically coupled to the free-standing portion, wherein the piezoelectric transducer comprises a piezoelectric material and a plurality of conductive electrodes disposed in electrically conductive contact with the piezoelectric material, the plurality of conductive electrodes extending from a base portion of the piezoelectric transducer.
G02F 1/00 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire
G02F 1/03 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des céramiques ou des cristaux électro-optiques, p.ex. produisant un effet Pockels ou un effet Kerr
G02F 1/035 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des céramiques ou des cristaux électro-optiques, p.ex. produisant un effet Pockels ou un effet Kerr dans une structure de guide d'ondes optique
92.
DIAGNOSTIC SYSTEM INCLUDING A BASE AND SINGLE-USE FLUIDIC DISPOSABLES
A diagnostic system for analyzing an analyte is described. In an embodiment the diagnostic system includes a fluidic single-use disposable and a base cooperatively coupleable thereto. In an embodiment, the fluidic single-use disposable comprises a sample processing subcomponent configured to receive a sample and emit signal light if the sample comprises an analyte; a fluidic single-use disposable housing encompassing the sample processing subcomponent, the fluidic single-use disposable housing comprising: a first major side; and a fluidic single-use disposable viewing window disposed in the first major side and positioned to allow light emitted from the sample processing subcomponent to pass through the fluidic single-use disposable viewing window. In an embodiment, the base comprises a base housing comprising: a first major side shaped to cooperatively couple with the first major side of the fluidic single-use disposable housing.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
G01N 21/03 - Dispositions ou appareils pour faciliter la recherche optique - Détails de structure des cuvettes
G01N 21/29 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection visuelle
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
G01N 21/27 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
G01N 15/14 - Recherche par des moyens électro-optiques
93.
IRON OXIDE NANOPARTICLE FOR SUPPRESSING DRUG-RESISTANT GENE FOR THE TREATMENT OF GLIOBLASTOMA
A nanoparticle for targeted siRNA delivery comprising an iron oxide core and a chitosan-polyethylene glycol-polyethylenimine copolymer coating surrounding the core, chlorotoxin covalently coupled to the coating, and an siRNA reversibly associated to the coating by non-covalent interaction. Methods for making the nanoparticle and methods for using the nanoparticle to suppress the expression of O6-methylguanine-DNA methyltransferase (MGMT), treating brain cancer, and killing cancer stem cells.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
The present disclosure describes a method for preparing a paper nanocomposite, including: continuously providing a first suspension that includes lignocellulosic pulp fibers, cellulose nanofibrils, carbon nanotubes, and a cationic surfactant; continuously adding a second suspension to the first suspension to provide a slurry, the second suspension includes lignocellulosic pulp fibers, cellulose nanofibrils, carbon nanotubes, and an anionic surfactant; depositing the slurry comprising the first and second suspensions onto the substrate; and dewatering the slurry to form the paper nanocomposite.
D21H 23/46 - Addition au papier formé le fluide étant versé ou s'écoulant en courant continu sur la surface, le courant entier étant entraîné par le papier
The present disclosure provides a device including a cylindrical member having a distal end and a proximal end. The cylindrical member includes a plurality of longitudinal slits positioned between the distal end and the proximal end to thereby create a plurality of strips positioned between the plurality of longitudinal slits. The device also includes an elongated hollow tube having a distal end and a proximal end. The elongated hollow tube is coupled to the proximal end of the cylindrical member. The device also includes a rod having a distal end and a proximal end.
In some embodiments, a method of controlling a follower vehicle in a vehicle platoon is provided. A follower vehicle controller in the follower vehicle determines a centralized control command based on centralized control information. The follower vehicle controller determines a local control command based on local sensing information using a delayed self reinforcement (DSR) technique. The follower vehicle controller applies weights to the centralized control command and the local control command. The follower vehicle controller combines the weighted centralized control command and the weighted local control command to create a combined control command. The follower vehicle controller uses the combined control command to control a speed of the corresponding follower vehicle.
G01S 19/40 - Correction de position, de vitesse ou d'attitude
B60W 30/16 - Contrôle de la distance entre les véhicules, p.ex. pour maintenir la distance avec le véhicule qui précède
H04W 4/46 - Services spécialement adaptés à des environnements, à des situations ou à des fins spécifiques pour les véhicules, p.ex. communication véhicule-piétons pour la communication de véhicule à véhicule
G05D 1/02 - Commande de la position ou du cap par référence à un système à deux dimensions
G01S 13/93 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques pour prévenir les collisions
Disclosed herein are embodiments of a hydrothermal reactor, such as a downflow hydrothermal reactor and methods of using the same. Also disclosed herein are system embodiments comprising the hydrothermal reactor. Method embodiments disclosed herein facilitate determining operation parameters for the hydrothermal reactor that give rise to efficient feedstock conversion to products while maintaining integrity of the reactor (e.g., avoiding corrosion) and providing safe operating conditions. The disclosed reactor and system embodiments facilitate situations where small scale and/or remote destruction of feedstocks (e.g., chemical warfare agents and/or environmental toxins) is needed.
B01J 19/26 - Réacteurs du type à injecteur, c. à d. dans lesquels la distribution des réactifs de départ dans le réacteur est effectuée par introduction ou injection au moyen d'injecteurs
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en général; Appareils appropriés
C02F 1/72 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par oxydation
C02F 1/74 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par oxydation au moyen de l'air
Disclosed are organic electrooptic materials. The electrooptic materials are functionalized by novel methods and structures. The electrooptic materials are structured with a head and a tail where the head and tail sequentially assemble into a non-centrosymmetric ordered array. The electrooptic materials are further structured in covalently bonded dimer pairs where one of the pairs is zwitterionic. The non-centrosymmetric ordered array bonds directly to electrodes which allows for efficient application of the electric field. The organic electrooptic materials disclosed offer greater hyperpolarizability, greater bandwidth, reduced operating voltage with less optical loss.
The present disclosure provides peptides, chimeric molecular constructs, and compositions thereof, that can bind volatile organic compounds (VOCs) and be utilized to distinguish VOC profiles, e.g., indicative of disease, as well as related methods. A VOC-based gas sensing approach described in the present specification can be an effective screening tool, due, at least in part, to its speed, ease of use, sensitivity, specificity, and because it does not rely on binding to specific nucleic acid fragments or proteins to function.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
